Roche (OTCMKTS:RHHBY) Stock Moved Down to Hold by UBS Group

Key Points

• UBS Group downgraded Roche from “strong buy” to “hold.” Other analyst views were mixed, and the consensus rating remained “Moderate Buy,” with a $60 average price target.
• Roche shares were reported down 2.5%; they opened at $59.18, within a 12-month range of $40.25 to $61.49.
• Institutional investors including S&CO Inc. increased their Roche holdings, while several others established new positions.

Roche (OTCMKTS:RHHBY - Get Free Report) was downgraded by research analysts at UBS Group from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Monday, Zacks reports.

Other analysts have also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a "hold" rating to a "buy" rating in a report on Friday, October 23rd. Royal Bank Of Canada started coverage on Roche in a report on Tuesday, September 8th. They issued an "outperform" rating on the stock. HSBC reiterated a "hold" rating on shares of Roche in a research report on Thursday, September 10th. Oddo Bhf raised Roche to an "outperform" rating in a research note on Tuesday, October 20th. Finally, Morgan Stanley upgraded Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 target price on the stock in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $60.00.

Roche Stock Down 2.5%

OTCMKTS RHHBY opened at $59.18 on Monday. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The company's 50 day simple moving average is $55.70 and its 200 day simple moving average is $53.80. Roche has a 12 month low of $40.25 and a 12 month high of $61.49.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RHHBY. S&CO Inc. grew its position in Roche by 163.0% during the 1st quarter. S&CO Inc. now owns 140,551 shares of the company's stock worth $6,880,000 after purchasing an additional 87,107 shares in the last quarter. Opal Capital LLC purchased a new stake in shares of Roche in the first quarter valued at $4,448,000. Associated Banc Corp purchased a new stake in shares of Roche in the third quarter valued at $1,740,000. GAMMA Investing LLC lifted its holdings in shares of Roche by 15.3% in the third quarter. GAMMA Investing LLC now owns 33,458 shares of the company's stock valued at $1,736,000 after purchasing an additional 4,443 shares in the last quarter. Finally, North Star Asset Management Inc. acquired a new stake in shares of Roche in the second quarter worth $1,351,000.

Roche Company Profile

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company's pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.